Sté Tunisienne des Maladies Respiratoires et d'Allergologie
Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis
![[Abstract Only] Atezolizumab for first-line treatment of PD-L1–selected patients with non–small-cell lung cancer](/media/k2/items/cache/2660be2b2df02c41fc17abdbfc676d66_L.jpg)
[Abstract Only] Atezolizumab for first-line treatment of PD-L1–selected patients with non–small-cell lung cancer
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC – New England Journal of Medicine Commentary: Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says – AJMC
The post [Abstract Only] Atezolizumab for first-line treatment of PD-L1–selected patients with non–small-cell lung cancer appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Non-inferiority RCT: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended VTE Treatment
- Systematic Review: Shorter Antibiotic Courses Often Prove Non-Inferior for Common Bacterial Infections
- Network Meta-analysis: Oseltamivir Fails to Improve Key Outcomes in Nonsevere Influenza
- Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies
- Introducing Our Free WhatsApp Channels for Daily Internal Medicine Articles!